On Thursday, a subsidiary of Japanese conglomerate Fujifilm Holdings Corp. said that it would open a massive biopharmaceutical manufacturing plant in central North Carolina in 2025. It will ultimately create 725 new jobs. Government officials and Fujifilm Diosynth Biotechnologies announced the overall $2 billion project in Holly Springs. It will be billed as the most extensive end-to-end biopharmaceutical manufacturing facility in North America. The company manufactures drugs and vaccines for other companies.
The company, Fujifilm Diosynth Biotechnologies, already has a campus in the nearby Research Triangle Park, which employs more than 600 people. According to the state’s Commerce Department, the company chose the Wake County site for building the plant in Texas. The company has already had locations in College Station, Texas, Denmark, and United Kingdom.
The Fujifilm Holdings President, Kenji Sukeno, said in a news release that they are delighted to expand their North Carolina footprint and fulfill their mission to help customers accelerate the development and supply of high-quality medicines to patients. The company has over thirty years of experience developing and manufacturing life-saving products like recombinant proteins, viral vectors, viral vaccines, monoclonal antibodies, and other large molecules and medical countermeasures.